Advertisement

Advertisement

Highlighted Articles  

 


Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

Sanchez, Sergio Vázquez, Narayanan Srihari, Haralabos Kalofonos, Petri Bono, Chaitali Babanrao Pisal, Yulia Hirschberg, Luca Dezzani, Qasim Ahmad, Eric Jonasch, on behalf of the PRINCIPAL Study Group

The Oncologist first published on March 13, 2019; doi:10.1634/theoncologist.2018-0787


T‐Cell Lymphopenia in Patients with Advanced Thyroid Carcinoma Is Associated with Poor Prognosis

Katrin Rabold, Paul R. Gielen, Esther D. Kers‐Rebel, Mihai G. Netea, Jan W.A. Smit, Gosse J. Adema, Romana T. Netea‐Maier

The Oncologist first published on January 3, 2019; doi:10.1634/theoncologist.2018-0422


Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine‐Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

Claudio Vernieri, Fabio Galli, Laura Ferrari, Paolo Marchetti, Sara Lonardi, Evaristo Maiello, Rosario V. Iaffaioli, Maria G. Zampino, Alberto Zaniboni, Sabino De Placido, Maria Banzi, Azzurra Damiani, Daris Ferrari, Gerardo Rosati, Roberto F. Labianca, Paolo Bidoli, Giovanni L. Frassineti, Mario Nicolini, Lorenzo Pavesi, Maria C. Tronconi, Angela Buonadonna, Sabrina Ferrario, Giovanni Lo Re, Vincenzo Adamo, Emiliano Tamburini, Mario Clerico, Paolo Giordani, Francesco Leonardi, Sandro Barni, Andrea Ciarlo, Luigi Cavanna, Stefania Gori, Saverio Cinieri, Marina Faedi, Massimo Aglietta, Maria Antista, Katia F. Dotti, Francesca Galli, Maria Di Bartolomeo, on behalf of TOSCA (Three or Six Colon Adjuvant) Investigators

The Oncologist first published on January 3, 2019; doi:10.1634/theoncologist.2018-0442


Nasoethmoidal Intestinal‐Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti‐Epidermal Growth Factor Receptor Therapy

Santiago Cabezas‐Camarero, Virginia de la Orden García, Vanesa García‐Barberán, Beatriz Mediero‐Valeros, Ahmad Issa Subhi‐Issa, Patricia Llovet García, Inmaculada Bando‐Polaino, Salomé Merino Menéndez, Pedro Pérez‐Segura, Eduardo Díaz‐Rubio

The Oncologist first published on January 2, 2019; doi:10.1634/theoncologist.2018-0387


A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

Alba A. Brandes, Miguel Gil‐Gil, Frank Saran, Antoine F. Carpentier, Anna K. Nowak, Warren Mason, Vittorina Zagonel, François Dubois, Gaetano Finocchiaro, George Fountzilas, Dana Michaela Cernea, Oliver Chinot, Rodica Anghel, Francois Ghiringhelli, Patrick Beauchesne, Giuseppe Lombardi, Enrico Franceschi, Martina Makrutzki, Chiedzo Mpofu, Hans‐Joerg Urban, Josef Pichler

The Oncologist first published on September 28, 2018; doi:10.1634/theoncologist.2018-0290


Cosmetic Consequences of Breast‐Conserving Treatment for Breast Cancer: Something Worth Talking About

Angelique Brands‐Appeldoorn, Sabrina Maaskant‐Braat, Karin Schenk, Rudi Roumen

The Oncologist first published on September 26, 2018; doi:10.1634/theoncologist.2017-0443


“I need to know what makes somebody tick …”: Challenges and Strategies of Implementing Shared Decision‐Making in Individualized Oncology

Joschka Haltaufderheide, Sebastian Wäscher, Bernhard Bertlich, Jochen Vollmann, Anke Reinacher‐Schick, Jan Schildmann

The Oncologist first published on September 6, 2018; doi:10.1634/theoncologist.2017-0615


Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single‐Arm, Open‐Label Phase IIIb CONSIGN Study

Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, Alberto Sobrero, Maria Banzi, Jean‐François Seitz, Carlo Barone, Marc Ychou, Marc Peeters, Baruch Brenner, Ralf Dieter Hofheinz, Evaristo Maiello, Thierry André, Andrea Spallanzani, Rocio Garcia‐Carbonero, Yull E. Arriaga, Udit Verma, Axel Grothey, Christian Kappeler, Ashok Miriyala, Joachim Kalmus, Alfredo Falcone, Alberto Zaniboni

The Oncologist first published on September 6, 2018; doi:10.1634/theoncologist.2018-0072


Expenditures on Oncology Drugs and Cancer Mortality‐to‐Incidence Ratio in Central and Eastern Europe

Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, Razvan Popescu, Robert Pirker, Tanja Čufer, Semir Bešlija, Alexandru Eniu, Vladimir Todorović, Katerina Kopečková, Galia Kurteva, Zorica Tomašević, Agim Sallaku, Snezhana Smichkoska, Žarko Bajić, Branimir Sikic

The Oncologist first published on September 4, 2018; doi:10.1634/theoncologist.2018-0093


Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs

Barbara Kiesewetter, Heying Duan, Wolfgang Lamm, Alexander Haug, Philipp Riss, Andreas Selberherr, Christian Scheuba, Markus Raderer

The Oncologist first published on on August 31, 2018; doi:10.1634/theoncologist.2018-0191


The Current and Evolving Landscape of First‐Line Treatments for Advanced Renal Cell Carcinoma

Emiliano Calvo, Camillio Porta, Viktor Grünwald, Bernard Escudier

The Oncologist first published on August 29, 2018; doi:10.1634/theoncologist.2018-0267


Definitive Radiotherapy in Invasive Vaginal Carcinoma: A Systematic Review

Consuelo Buttigliero, Frances A. Shepherd, Fabrice Barlesi, Brian Schwartz, Sergey Orlov, Adolfo G. Favaretto, Armando Santoro, Vera Hirsh, Rodryg Ramlau, Adele R. Blackler, Joanna Roder, David Spigel, Silvia Novello, Wallace Akerley, Giorgio V. Scagliotti

The Oncologist first published on August 23, 2018; doi:10.1634/theoncologist.2017-0546


Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non‐Small Cell Lung Cancer

Consuelo Buttigliero, Frances A. Shepherd, Fabrice Barlesi, Brian Schwartz, Sergey Orlov, Adolfo G. Favaretto, Armando Santoro, Vera Hirsh, Rodryg Ramlau, Adele R. Blackler, Joanna Roder, David Spigel, Silvia Novello, Wallace Akerley, Giorgio V. Scagliotti

The Oncologist first published on August 23, 2018; doi:10.1634/theoncologist.2018-0089


Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?

Fotios Loupakis, Marta Schirripa, Rossana Intini, Francesca Bergamo, Roberta Bertorelle, Matteo Fassan, Vincenzo Dadduzio, Stefano Merigliano, Pierluigi Pilati, Emanuele Luca Damiano Urso, Umberto Cillo, Massimo Rugge, Sara Lonardi, Vittorina Zagonel

The Oncologist first published on August 17, 2018;doi:10.1634/theoncologist.2018-0180


Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

Pilar García‐Alfonso, Manuel Benavides, Esther Falcó, Andrés Muñoz, Auxiliadora Gómez, Javier Sastre, Fernando Rivera, Clara Montagut, Mercedes Salgado, Amelia López‐Ladrón, Rafael López, Inmaculada Ruiz de Mena, Gema Durán, Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)

The Oncologist first published on August 17, 2018; doi:10.1634/theoncologist.2018-0316


Clinicopathological and Treatment‐Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology

Gaia Griguolo, Stephane Pouderoux, Maria Vittoria Dieci, William Jacot, Céline Bourgier, Federica Miglietta, Nelly Firmin, Pierfranco Conte, Marie Viala, Valentina Guarneri, Amélie Darlix

The Oncologist first published on August 17, 2018; doi:10.1634/theoncologist.2018-0200


Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer‐Associated Thrombosis: The Observational ROADMAP‐CAT Study

Konstantinos Syrigos, Dimitra Grapsa, Rabiatou Sangare, Ilias Evmorfiadis, Annette K. Larsen, Patrick Van Dreden, Paraskevi Boura, Andriani Charpidou, Elias Kotteas, Theodoros N. Sergentanis, Ismail Elalamy, Anna Falanga, Grigoris T. Gerotziafas

The Oncologist first published on August 13, 2018; doi:10.1634/theoncologist.2017-0530


Effectiveness of First‐Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA

Matteo Franchi, Sandro Barni, Giovanna Tagliabue, Paolo Ricci, Walter Mazzucco, Rosario Tumino, Antonietta Caputo, Giovanni Corrao, on behalf of the GRETA working group

The Oncologist first published on August 10, 2018; doi:10.1634/theoncologist.2017-0314


NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancerp

Vanesa Gregorc, Raffaele Cavina, Sivia Novello, Francesco Grossi, Chiara Lazzari, Enrica Capelletto, Carlo Genova, Giulia Salini, Antonio Lambiase, Armando Santoro

The Oncologist first published on August 3, 2018; doi:10.1634/theoncologist.2018-0292


Non‐Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group

Ales Ryska, Rares Buiga, Albena Fakirova, Izidor Kern, Włodzimierz Olszewski, Lukas Plank, Sven Seiwerth, Erika Toth, Eri Zivka, Christiane Thallinger, Christoph Zielinski, Luka Brcic

The Oncologist first published on August 3, 2018; doi:10.1634/theoncologist.2018-0008


Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma

Shai Rosenberg, Francois Ducray, Agusti Alentorn, Caroline Dehais, Nabila Elarouci, Aurelie Kamoun, Yannick Marie, Marie‐Laure Tanguy, Aurélien De Reynies, Karima Mokhtari, Dominique Figarella‐Branger, Jean‐Yves Delattre, Ahmed Idbaih, POLA Network

The Oncologist 2018 first published on July 17, 2018; doi:10.1634/theoncologist.2017-0495


Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study

Mariette Labots, Johannes C. Van der Mijn, Henk Dekker, Rita Ruijter, Thang V. Pham, Hans J. Van der Vliet, Jacobus J.M. Van der Hoeven, Gerrit A. Meijer, Henk M.W. Verheul

The Oncologist 2018 first published on July 17, 2018; doi:10.1634/theoncologist.2018-0263


Training for Medical Oncologists on Shared Decision‐Making About Palliative Chemotherapy: A Randomized Controlled Trial

Inge Henselmans, Hanneke W.M. van Laarhoven, Hanneke C.J.M. de Haes, Meltem Tokat, Ellen G. Engelhardt, Pomme E.A. van Maarschalkerweerd, Marleen Kunneman, Petronella B. Ottevanger, Serge E. Dohmen, Geert‐Jan Creemers, Dirkje W. Sommeijer, Filip Y.F.L. de Vos, Ellen M.A. Smets

The Oncologist first published on June 29, 2018; doi:10.1634/theoncologist.2018-0090


Cognitive Changes After Adjuvant Treatment in Older Adults with Early‐Stage Breast Cancer

Marie Lange, Natacha Heutte, Sabine Noal, Olivier Rigal, Jean‐Emmanuel Kurtz, Christelle Lévy, Djelila Allouache, Chantal Rieux, Johan Lefel, Bénédicte Clarisse, Alexandra Leconte, Corinne Veyret, Philippe Barthélémy, Nadine Longato, Laure Tron, Hélène Castel, Francis Eustache, Bénédicte Giffard, Florence Joly

The Oncologist first published on June 22, 2018; doi:10.1634/theoncologist.2017-0570


Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

Loïc Chaigneau, Anna Patrikidou, Isabelle Ray‐Coquard, Thibaud Valentin, Claude Linassier, Jacques Olivier Bay, Laurence Moureau Zabotto, Emmanuelle Bompas, Sophie Piperno‐Neumann, Nicolas Penel, Thierry Alcindor, Maryline Laigre, Cecile Guillemet, Sebastien Salas, Anne Hugli, Julien Domont, Marie Pierre Sunyach, Axel Lecesne, Jean Yves Blay, Virginie Nerich, Nicolas Isambert

The Oncologist 2018 first published on June 22, 2018; doi:10.1634/theoncologist.2017-0136


Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

Jaume Capdevila, Alexandre Teulé, Jorge Barriuso, Daniel Castellano, Carlos Lopez, Jose Luis Manzano, Vicente Alonso, Rocío García‐Carbonero, Emma Dotor, Ignacio Matos, Ana Custodio, Oriol Casanovas, Ramon Salazar, on behalf of the EVERLAR study investigators

The Oncologist first published on May 23, 2018; doi:10.1634/theoncologist.2017-0622


Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients

Sebastiano Mercadante, Claudio Adile, Gaetano Lanzetta, Kyriaki Mystakidou, Marco Maltoni, Luiz Guilherme Soares, Stefano De Santis, Patrizia Ferrera, Marco Valenti, Marta Rosati, Romina Rossi, Andrea Cortegiani, Francesco Masedu, Franco Marinangeli, Federica Aielli

The Oncologist first published on May 16, 2018; doi:10.1634/theoncologist.2017-0668


Trifluridine/Tipiracil (TAS‐102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

Chiara Cremolini, Daniele Rossini, Erika Martinelli, Filippo Pietrantonio, Sara Lonardi, Silvia Noventa, Emiliano Tamburini, Giovanni Luca Frassineti, Stefania Mosconi, Federico Nichetti, Sabina Murgioni, Teresa Troiani, Beatrice Borelli, Gemma Zucchelli, Alessandro Dal Maso, Vincenzo Sforza, Gianluca Masi, Carlotta Antoniotti, Maria Di Bartolomeo, Rosalba Miceli, Fortunato Ciardiello, Alfredo Falcone

The Oncologist first published on May 8, 2018; doi:10.1634/theoncologist.2017-0573


Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab

Asunción Díaz‐Serrano, Barbara Angulo, Carolina Dominguez, Roberto Pazo‐Cid, Antonieta Salud, Paula Jiménez‐Fonseca, Ana Leon, Maria Carmen Galan, Maria Alsina, Fernando Rivera, J. Carlos Plaza, Luis Paz‐Ares, Fernando Lopez‐Rios, Carlos Gómez‐Martín

The Oncologist first published on April 26, 2018; doi:10.1634/theoncologist.2017-0379


Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?

Pellegrino Musto

The Oncologist 2018; 23:511-515; first published on April 26, 2018; doi:10.1634/theoncologist.2018-0097


Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study)

Vittorio Stefoni, Cinzia Pellegrini, Alessandro Broccoli, Luca Baldini, Monica Tani, Emanuele Cencini, Amalia Figuera, Michela Ansuinelli, Elisa Bernocco, Maria Cantonetti, Maria Christina Cox, Filippo Ballerini, Chiara Rusconi, Carlo Visco, Luca Arcaini, Angelo Fama, Roberto Marasca, Stefano Volpetti, Alessia Castellino, Catello Califano, Marina Cavaliere, Guido Gini, Anna Marina Liberati, Gerardo Musuraca, Anna Lucania, Giuseppina Ricciuti, Lisa Argnani, Pier Luigi Zinzani

The Oncologist first published on April 19, 2018; doi:10.1634/theoncologist.2017-0597


Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First‐Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials

Eugenie Younger, Saskia Litière, Axel Le Cesne, Olivier Mir, Hans Gelderblom, Antoine Italiano, Sandrine Marreaud, Robin Lewis Jones, Alessandro Gronchi, Winette T.A. van der Graaf

The Oncologist first published on April 12, 2018; doi:10.1634/theoncologist.2017-0598


European Articles Archive

Links to other domains will open in a new tab or window.